Clinical Trials Logo

Pancreas-Kidney Transplantation clinical trials

View clinical trials related to Pancreas-Kidney Transplantation.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02234349 Completed - Clinical trials for Kidney Transplantation

Bile Acids and Incretins in Pancreas Kidney Transplant Patients

ITABI
Start date: September 5, 2013
Phase: N/A
Study type: Interventional

Pancreas Kidney Transplantation (PKT) is the prominent treatment for type 1 diabetic patients with chronic kidney disease and improves patients' outcome. However, in spite of an optimized systemic insulin substitution, altered glucose metabolism and beta cell function are reported in these patients. The mechanisms behind these abnormalities are still unclear. Duodena-pancreatic anastomosis is performed in a heterotopic site (ileum) and thus could change physical and chemical properties of intestinal secretions, gut flora, as well as intestinal permeability. The effect of this procedure on gut derived metabolic factors, the enterohepatic cycle of bile acids, incretin secretion and intestinal flora have never been studied. This pilot prospective, study is aimed to evaluate the modification of bile acids concentrations and composition in PKT subjects, and the impact in glucose and incretin metabolism (measured by oral glucose tolerance test) one year after transplantation. The results will be compared to those of kidney transplant patients and control subjects.

NCT ID: NCT00316810 Completed - Clinical trials for Pancreas-Kidney Transplantation

Simultaneous Pancreas-kidney Transplantation With Campath Protocol

Start date: April 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine and compare the efficacy of Campath-1H/Tacrolimus versus ATG/Tacrolimus/MMF therapy in conjunction with initial short-term steroids in Type 1-diabetic patients undergoing simultaneous pancreas-kidney allograft transplantation as well as to evaluate the safety of Campath-1H/Tacrolimus versus ATG/Tacrolimus/MMF in terms of drug-related complications and immunosuppression-associated complications.